Literature DB >> 24748541

HIC2 is a novel dosage-dependent regulator of cardiac development located within the distal 22q11 deletion syndrome region.

Iain M Dykes1, Kelly Lammerts van Bueren1, Rebekah J Ashmore1, Thomas Floss1, Wolfgang Wurst1, Dorota Szumska1, Shoumo Bhattacharya1, Peter J Scambler2.   

Abstract

RATIONALE: 22q11 deletion syndrome arises from recombination between low-copy repeats on chromosome 22. Typical deletions result in hemizygosity for TBX1 associated with congenital cardiovascular disease. Deletions distal to the typically deleted region result in a similar cardiac phenotype but lack in extracardiac features of the syndrome, suggesting that a second haploinsufficient gene maps to this interval.
OBJECTIVE: The transcription factor HIC2 is lost in most distal deletions, as well as in a minority of typical deletions. We used mouse models to test the hypothesis that HIC2 hemizygosity causes congenital heart disease. METHODS AND
RESULTS: We created a genetrap mouse allele of Hic2. The genetrap reporter was expressed in the heart throughout the key stages of cardiac morphogenesis. Homozygosity for the genetrap allele was embryonic lethal before embryonic day E10.5, whereas the heterozygous condition exhibited a partially penetrant late lethality. One third of heterozygous embryos had a cardiac phenotype. MRI demonstrated a ventricular septal defect with over-riding aorta. Conditional targeting indicated a requirement for Hic2 within the Nkx2.5+ and Mesp1+ cardiovascular progenitor lineages. Microarray analysis revealed increased expression of Bmp10.
CONCLUSIONS: Our results demonstrate a novel role for Hic2 in cardiac development. Hic2 is the first gene within the distal 22q11 interval to have a demonstrated haploinsufficient cardiac phenotype in mice. Together our data suggest that HIC2 haploinsufficiency likely contributes to the cardiac defects seen in distal 22q11 deletion syndrome.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  22q11 deletion syndrome; HIC2 protein, human; Mesp1 protein, mouse; developmental biology; genetics; heart septal defects, ventricular; models, animal

Mesh:

Substances:

Year:  2014        PMID: 24748541     DOI: 10.1161/CIRCRESAHA.115.303300

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  15 in total

Review 1.  Opportunities lost and gained: Changes in progenitor competence during nervous system development.

Authors:  Dylan R Farnsworth; Chris Q Doe
Journal:  Neurogenesis (Austin)       Date:  2017-05-26

2.  Determinants of orofacial clefting II: Effects of 5-Aza-2'-deoxycytidine on gene methylation during development of the first branchial arch.

Authors:  Ratnam S Seelan; Partha Mukhopadhyay; Dennis R Warner; Irina A Smolenkova; M Michele Pisano; Robert M Greene
Journal:  Reprod Toxicol       Date:  2016-12-05       Impact factor: 3.143

3.  Mouse and human CRKL is dosage sensitive for cardiac outflow tract formation.

Authors:  Silvia E Racedo; Donna M McDonald-McGinn; Jonathan H Chung; Elizabeth Goldmuntz; Elaine Zackai; Beverly S Emanuel; Bin Zhou; Birgit Funke; Bernice E Morrow
Journal:  Am J Hum Genet       Date:  2015-02-05       Impact factor: 11.025

4.  HIC2 controls developmental hemoglobin switching by repressing BCL11A transcription.

Authors:  Peng Huang; Scott A Peslak; Ren Ren; Eugene Khandros; Kunhua Qin; Cheryl A Keller; Belinda Giardine; Henry W Bell; Xianjiang Lan; Malini Sharma; John R Horton; Osheiza Abdulmalik; Stella T Chou; Junwei Shi; Merlin Crossley; Ross C Hardison; Xiaodong Cheng; Gerd A Blobel
Journal:  Nat Genet       Date:  2022-08-08       Impact factor: 41.307

Review 5.  22q11.2 deletion syndrome.

Authors:  Donna M McDonald-McGinn; Kathleen E Sullivan; Bruno Marino; Nicole Philip; Ann Swillen; Jacob A S Vorstman; Elaine H Zackai; Beverly S Emanuel; Joris R Vermeesch; Bernice E Morrow; Peter J Scambler; Anne S Bassett
Journal:  Nat Rev Dis Primers       Date:  2015-11-19       Impact factor: 52.329

6.  Histone Modifier Genes Alter Conotruncal Heart Phenotypes in 22q11.2 Deletion Syndrome.

Authors:  Tingwei Guo; Jonathan H Chung; Tao Wang; Donna M McDonald-McGinn; Wendy R Kates; Wanda Hawuła; Karlene Coleman; Elaine Zackai; Beverly S Emanuel; Bernice E Morrow
Journal:  Am J Hum Genet       Date:  2015-11-19       Impact factor: 11.025

7.  A French multicenter study of over 700 patients with 22q11 deletions diagnosed using FISH or aCGH.

Authors:  Céline Poirsier; Justine Besseau-Ayasse; Caroline Schluth-Bolard; Jérôme Toutain; Chantal Missirian; Cédric Le Caignec; Anne Bazin; Marie Christine de Blois; Paul Kuentz; Marie Catty; Agnès Choiset; Ghislaine Plessis; Audrey Basinko; Pascaline Letard; Elisabeth Flori; Mélanie Jimenez; Mylène Valduga; Emilie Landais; Hakima Lallaoui; François Cartault; James Lespinasse; Dominique Martin-Coignard; Patrick Callier; Céline Pebrel-Richard; Marie-France Portnoi; Tiffany Busa; Aline Receveur; Florence Amblard; Catherine Yardin; Radu Harbuz; Fabienne Prieur; Nathalie Le Meur; Eva Pipiras; Pascale Kleinfinger; François Vialard; Martine Doco-Fenzy
Journal:  Eur J Hum Genet       Date:  2015-10-28       Impact factor: 4.246

Review 8.  Molecular genetics of 22q11.2 deletion syndrome.

Authors:  Bernice E Morrow; Donna M McDonald-McGinn; Beverly S Emanuel; Joris R Vermeesch; Peter J Scambler
Journal:  Am J Med Genet A       Date:  2018-10       Impact factor: 2.802

9.  Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.

Authors:  Quinlan L Sievers; Georg Petzold; Richard D Bunker; Aline Renneville; Mikołaj Słabicki; Brian J Liddicoat; Wassim Abdulrahman; Tarjei Mikkelsen; Benjamin L Ebert; Nicolas H Thomä
Journal:  Science       Date:  2018-11-02       Impact factor: 47.728

10.  Recurrent Rare Genomic Copy Number Variants and Bicuspid Aortic Valve Are Enriched in Early Onset Thoracic Aortic Aneurysms and Dissections.

Authors:  Siddharth Prakash; Shao-Qing Kuang; Ellen Regalado; Dongchuan Guo; Dianna Milewicz
Journal:  PLoS One       Date:  2016-04-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.